title: Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action.
abstract: Non-competitive NMDA receptor antagonists are widely used as pharmacological models of schizophrenia due to their ability to evoke the symptoms of the illness. Likewise, serotonergic hallucinogens, acting on 5-HT(2A) receptors, induce perceptual and behavioural alterations possibly related to psychotic symptoms. The neurobiological basis of these alterations is not fully elucidated. Data obtained in recent years revealed that the NMDA receptor antagonist phencyclidine (PCP) and the serotonergic hallucinogen 1-(2,5-dimethoxy-4-iodophenyl-2-aminopropane; DOI) produce a series of common actions in rodent prefrontal cortex (PFC) that may underlie psychotomimetic effects. Hence, both agents markedly disrupt PFC function by altering pyramidal neuron discharge (with an overall increase) and reducing the power of low frequency cortical oscillations (LFCO; < 4 Hz). In parallel, PCP increased c-fos expression in excitatory neurons of various cortical areas, the thalamus and other subcortical structures, such as the amygdala. Electrophysiological studies revealed that PCP altered similarly the function of the centromedial and mediodorsal nuclei of the thalamus, reciprocally connected with PFC, suggesting that its psychotomimetic properties are mediated by an alteration of thalamocortical activity (the effect of DOI was not examined in the thalamus). Interestingly, the observed effects were prevented or reversed by the antipsychotic drugs clozapine and haloperidol, supporting that the disruption of PFC activity is intimately related to the psychotomimetic activity of these agents. Overall, the present experimental model can be successfully used to elucidate the neurobiological basis of schizophrenia symptoms and to examine the potential antipsychotic activity of new drugs in development.
authors.affiliation: Department of Neurochemistry and Neuropharmacology, Institut d'Investigacions Biomèdiques de Barcelona, (IIBB-CSIC), Barcelona, Spain.
authors.forename: Pau
authors.initials: P
authors.lastname: Celada
authors.forename: Laia
authors.initials: L
authors.lastname: Lladó-Pelfort
authors.forename: N
authors.initials: N
authors.lastname: Santana
authors.forename: L
authors.initials: L
authors.lastname: Kargieman
authors.forename: Eva
authors.initials: E
authors.lastname: Troyano-Rodriguez
authors.forename: M S
authors.initials: MS
authors.lastname: Riga
authors.forename: Francesc
authors.initials: F
authors.lastname: Artigas
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D004195:Disease Models, Animal; D006801:Humans; D007215:Indophenol / Q000031:analogs & derivatives*; D010622:Phencyclidine; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D012559:Schizophrenia / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D012565:Schizophrenic Psychology; D013787:Thalamic Nuclei / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*
chemical_list: D014150:Antipsychotic Agents; C113896:dimethoxy-4-indophenyl-2-aminopropane; D007215:Indophenol; D010622:Phencyclidine